Loke R H, Anderson M G, Coleman J C, Tsiquaye K N, Zuckerman A J, Murray-Lyon I M
J Med Virol. 1987 Jan;21(1):97-9. doi: 10.1002/jmv.1890210113.
Suramin has recently been shown to inhibit the activity of the duck hepatitis B virus DNA polymerase (DHBV DNAp) in vitro. However, we found no demonstrable in vivo suppression of human hepatitis B virus DNA polymerase (HBV DNAp) activity in three male patients with severe chronic active hepatitis. Suramin treatment resulted in prolongation of the prothrombin time in all cases and a rise in bilirubin in two and it may have led to haemorrhage from oesophageal varices in one patient and to hepatic encephalopathy in another. Its use in chronic hepatitis is not recommended.
最近研究表明，苏拉明在体外可抑制鸭乙型肝炎病毒DNA聚合酶（DHBV DNAp）的活性。然而，我们发现，在三名患有严重慢性活动性肝炎的男性患者中，未观察到苏拉明对人乙型肝炎病毒DNA聚合酶（HBV DNAp）活性有明显的体内抑制作用。所有病例中，苏拉明治疗均导致凝血酶原时间延长，两例胆红素升高，且可能导致一名患者食管静脉曲张出血，另一名患者发生肝性脑病。不建议将其用于慢性肝炎的治疗。
